急诊静脉溶栓治疗急性心肌梗死47例临床分析

目的探讨在急诊科静脉溶栓治疗急性心肌梗死(AMI)患者的临床效果及安全性.方法AMI患者96例,在急诊科经静脉给予尿激酶(UK)溶栓治疗49例为观察组(A组),未溶栓治疗患者47例为对照组(B组),二组治疗除观察组使用UK外,其余治疗方法相同.结果观察组住院4周病死率为6.12%(3/49),对照组为25.53%(12/47),二组比较差异有统计学意义(P＜0.05).观察组心力衰竭发生率为20.40%(10/49),对照组为51.06%(24/47),二组比较差异有统计学意义(P＜0.05).观察组冠脉再通率为53.06%(26/49),对照组为14.80%(7/47).二组再通率比较差异有统计学意义(P＜0.05).观察组未见严重的大出血或脑出血.结论在急诊科溶栓治疗AMI可提高冠状动脉再通率,减少心力衰竭发生,保护心功能,降低患者的病死率,明显改善预后.

CLINICAL ANALYSIS OF INTRAVENOUS THROMBOLYSIS IN EMERGENCY DEPARTMENT FOR 47 PATIENTS WITH ACUTE MYOCARDIAL INFARCTION

Objective To study clinical efficacy of thrombolytic therapy in Emergency Department for acute myocardial infarction(AMI). Methods 96 patients with AMI were divided into two groups.49 patients with AMI received urokinase from intravenous as treatment group.47 patients with AMI didn't receive urokinase from intravenous as control group. Other therapy was same in two groups. Results Death rate was 6.12%(3/49) in treatment group and 25.53%(12/47) in control group for 4 weeks hospitalization. The rate of heart failure was 53.06%(26/49) in treatment group and 14.80% ( 7/47 ).There were significant differences between two groups (P<0.05) above results. Conclusion Intravenous thrombolysis for patient with AMI could increase the reperfusion rate,reduce heart failure for protecting heart function and death rate,to improve remarkably prognosis.